Rani Therapeutics Narrows Loss Yet Stock Plummets 11%

Rani Therapeutics (RANI) announced fiscal 2025 Q4 results on March 26, 2026. The company reported a narrowed net loss and significant strategic milestones, including a major partnership with Chugai and the initiation of Phase 1 trials for its lead oral biologic candidate.

Revenue

The total revenue of Rani Therapeutics increased by 42.1% to $1.46 million in 2025 Q4, up from $1.03 million in the corresponding period of 2024.

Earnings/Net Income

Rani Therapeutics narrowed losses to $0.08 per share in 2025 Q4 from a loss of $0.16 per share in 2024 Q4, representing a 45.6% improvement. Meanwhile, the company successfully narrowed its net loss to $-9.07 million in 2025 Q4, reducing losses by 42.3% compared to the $-15.72 million net loss reported in 2024 Q4. The Company has sustained losses for 3 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The EPS miss indicates continued challenges in achieving profitability despite the narrowing loss trend.

Price Action

The stock price of Rani Therapeutics has tumbled 11.48% during the latest trading day, has dropped 6.09% during the most recent full trading week, and has plummeted 17.56% month-to-date.

Post Earnings Price Action Review

The strategy of buying Rani Therapeutics (RANI) shares 30 days after its quarterly earnings report released over the past three years resulted in a significant loss. The strategy yielded a return of -94.51%, underperforming the benchmark by 134.75%. The Sharpe ratio was -0.97, indicating substantial risk, while the maximum drawdown was 94.95%, highlighting the strategy's vulnerability during market downturns.

CEO Commentary

Talat Imran, Chief Executive Officer of Rani Therapeutics, declared 2025 a transformational year marked by the initiation of the Phase 1 study for RT-114, the company's first orally administered GLP-1/GLP-2 dual agonist. He emphasized the robust preclinical evidence supporting the RaniPill® platform, which demonstrated successful oral delivery of complex incretin-based therapies. Imran highlighted the strategic strengthening of the balance sheet through an oversubscribed $60.3 million private placement and a high-value collaboration with Chugai worth up to $1.085 billion. Looking ahead, he expressed confidence in advancing the first oral dual agonist into clinical development and unlocking the platform's potential across high-value therapeutic areas in 2026.

Guidance

Management projects that cash and marketable securities totaling $49.7 million will fund operations into the fourth quarter of 2027, providing a secure runway for clinical execution. The company anticipates advancing the Phase 1 trial of RT-114 and continuing to validate the RaniPill® platform through upcoming preclinical and clinical milestones. Qualitative expectations focus on executing strategic partnership objectives and expanding the pipeline of orally administered biologics, with no specific revenue guidance provided beyond the operational runway.

Additional News

Rani Therapeutics announced a strategic collaboration and license agreement with Chugai Pharmaceutical Co. valued at up to $1.085 billion, securing funding for multiple high-value therapeutics. This deal includes an option for five additional targets, significantly expanding the company's commercial potential. Additionally, the company completed a $60.3 million oversubscribed private placement led by Samsara BioCapital, with participation from prominent investors like RA Capital Management and Invus, reinforcing its financial stability. In a leadership update, Rani Therapeutics appointed a new Head of Strategy to drive future growth initiatives. These developments, occurring alongside the earnings release, underscore a period of aggressive strategic expansion and strengthened capitalization for the clinical-stage biotherapeutics firm.

Image rule:

Insert exactly one "

" on a NEW line AFTER a paragraph, and BEFORE the next section heading. Do NOT place it at the very end of or very top of the article. Hard constraints: - Do NOT place any placeholder at the beginning or end of the article. - Do NOT place placeholders consecutively without at least one "

" between them. - Preserve all existing text and line breaks; only add the required placeholders and the specified "

".